Research What we do and how? Teams Meet our people News What's happening Photogallery Be in the picture Our Partners Join our projects Contacts Addresses, emails, phones…
Research Research
Laboratory Instruments Instruments purchased through European Regional Development Fund. CZ.02.1.01/0.0/0.0/15_003/0000495
Publications Articles published under the Project FIT
Patents And Inventions Patents filed under Project FIT
Teams Teams
Virology doc.RNDr. Daniel RŮŽEK, Ph.D.
Chemistry And Toxicology RNDr. Miroslav MACHALA, CSc.
Biotechnology and Immunology UPOL Prof. MUDr. Mgr. Milan RAŠKA, Ph.D.
News News
International Symposium - Innovative Health Care Technologies in Chemistry and Virology International Symposium​“Innovative Health Care Technologies in Chemistry and Virology”took place on 27.5.2019 at Veterinary Research Institute Brno, Czech Republic
Photogallery Photogallery
Laboratories and VRI campus Place for our scientists
Laboratory Instruments These instruments were financed by Regional Development Fund. CZ.02.1.01/0.0/0.0/15_003/0000495
Events photos Conferences, seminars, visits ...
You are here:

Dr. Amotz Shemi lecture

Last week the VRI was pleased to welcome Dr Amotz Shemi from Israel as an honoured guest and speaker. He was invited by the Director of Project FIT, Prof Andrew Miller, as part of the OPVVV requirements to build meaningful international connections and collaborations for Project FIT and for the VRI in general. Dr Shemi was trained as a theoretical physicist and is now  a world leading expert on the use of RNA interference to treat cancer. The highlight of the visit was Dr Shemi’s lecture on “RNAi-based treatment for solid tumors non-clinical and clinical evidence”, which was followed by many questions from the Czech audience drawn from research groups in the VRI and other institutes/universities in Brno. Throughout Dr Shemi’s visit, there were extensive scientific discussions involving Dr Shemi and Prof Miller, also involving other Scientific directors of Project FIT, notably Dr Jaroslav Turanek and Dr Miroslav Machala, plus senior members of their research teams. Just prior to his departure, Dr Shemi was given a tour of the VRI campus during which he informed us that he was very impressed by the equipment and laboratories available to the VRI and to the Project FIT in particular. 

Overall, Dr Shemi’s visit appears to have been a great success for all parties. The VRI and Silenseed agreed to sign a non-disclosure agreement (NDA) to enable confidential discussions to proceed regarding future research and development collaborations. Given such mutual enthusiasm, discussions are now already underway. Gratifyingly, for all those who live and work in Brno, Dr Shemi also pronounced himself delighted with the “authentic character and quality” of Brno in comparison to Prague. So he looks forward to his next visit to Brno and we look forward to future, fruitful collaborations.



Dr. Shemi is Silenseed’s co-founder and has served as the company’s Chairman of the Board of Directors and Chief Executive Officer since incorporation in 2008. Prior to founding Silenseed, from 2005 to 2008, Dr. Shemi served as the Senior Vice President Technologies at Medinol Ltd., a world leader in design, development and manufacturing of stent and stent delivery systems. Prior to that time, Dr. Shemi was the chief executive of several private Israeli technology companies, including Color-Chip Ltd. Dr. Shemi holds a Ph.D. degree in Physics from the Tel Aviv University. He is a single author and co-author of many scientific papers and a single inventor and co-inventor of more than a dozen of patents.

Silenseed LTD is a clinical stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors. The company’ novel drugs, used together with the new delivery system, the LODER™ (LOcal Drug EluteR), have the potential to be one of the most highly effective treatments for solid tumor cancers. Diseases that currently are included in the company’s pipeline are pancreatic cancer, prostate cancer and certain brain cancers.

Doctor in with sweet look at work in lab.